30 closest matches · ranked by relevance
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Ovarian Cancer · Fallopian Tube Cancer
Primary: Median Time to Treatment Termination (TTT) — 78 days
Malignant Ovarian Epithelial Tumor · Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma
Primary: Tumor Response — 16.7 percentage of patients
Polycystic Ovary Syndrome
Primary: Estradiol During Phase I and Phase II — 451.7; 116; 247.2; 131.4 pmol/L
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Number of Participants Assessed for Safety and Tolerability as Assessed by NCI CTCAE v3.0 — 3; 3; 4; 2 Participants
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants
Ovarian Cancer
Primary: Increase in SGK1 mRNA Expression Level — 1.5; 6.1 fold change
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 0; 0 participants
Ovarian Cancer · Primary Peritoneal Cancer
Primary: The Cystostatic, Anti-tumor Activity of the Combination of Gleevec and Gemzar Via Progression-free Survival for at Least Six Months in Patients With Recurrent or…
Ovarian Carcinoma
Primary: Median Proportion Cells That Are Apoptotic in Epithelial Ovarian Tissue — .093; .115 proportion of total cells
Borderline Ovarian Serous Tumor · Low Grade Ovarian Serous Adenocarcinoma · Micropapillary Serous Carcinoma
Primary: Tumor Response — 15.4 percentage of patients
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Primary: Recurrence-Free Survival — 58.1; 55.6 percentage of patients
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression (TTP)
Ovarian Cancer
Primary: Best Overall Tumor Response — 6; 25; 10; 5 participants
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
Ovarian Cancer
Primary: PFS — 29.8 Months
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Patients With Response — 9; 21; 24 Participants
Peritoneal Cancer · Ovarian Cancer · Neoplasms, Ovarian
Primary: Best Biochemical Response (Cancer Antigen [CA-125]) — 6; 25; 56; 3 percentage of participants
Childhood Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Overall Survival (OS) — 86; 56 percentage of participants
Ovarian Carcinoma · Fallopian Tube Cancer · Peritoneal Carcinoma
Primary: Safety and Tolerability (Adverse Event Reported Per CTCAE v5) — 6; 0; 6; 6 Participants
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Objective Tumor Response — 21; 32; 17; 1 participants
Ovarian Cancer · Fallopian Tube Adenocarcinoma · Primary Peritoneal Cavity Cancer
Primary: Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events — 0; 0; 0 Participants
Ovarian Cancer
Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants
CNS Germ Cell Tumor
Primary: Response Rate — 0; 0; 4; 2 Participants
Borderline Ovarian Serous Tumor · Micropapillary Serous Carcinoma · Ovarian Serous Adenocarcinoma
Primary: Progression-free Survival (PFS) — 7.2; 13.0 months
Brenner Tumor · Fallopian Tube Cancer · Ovarian Clear Cell Cystadenocarcinoma
Primary: Time to Progression — 4.07 months